Adial Pharmaceuticals, Inc.
ADIL
$0.3721
$0.00010.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.16% | 1.50% | -10.07% | -13.01% | -22.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.14% | 34.69% | 20.27% | 5.53% | -18.26% |
| Operating Income | -14.14% | -34.69% | -20.27% | -5.53% | 18.26% |
| Income Before Tax | 30.66% | 20.37% | -88.48% | -70.40% | -37.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.66% | 20.37% | -88.48% | -70.40% | -37.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -101.01% | -105.04% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.97% | -2.94% | -157.60% | -114.95% | -57.04% |
| EBIT | -14.14% | -34.69% | -20.27% | -5.53% | 18.26% |
| EBITDA | -14.14% | -34.69% | -20.28% | -5.53% | 18.26% |
| EPS Basic | 74.39% | 49.61% | 8.01% | 30.73% | 37.05% |
| Normalized Basic EPS | 58.15% | 56.50% | 21.65% | 43.91% | 43.62% |
| EPS Diluted | 74.39% | 49.61% | 8.10% | 30.78% | 37.08% |
| Normalized Diluted EPS | 58.15% | 56.50% | 21.65% | 43.91% | 43.62% |
| Average Basic Shares Outstanding | 176.19% | 202.35% | 239.95% | 248.05% | 150.67% |
| Average Diluted Shares Outstanding | 176.19% | 202.35% | 239.95% | 248.05% | 150.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |